Susquehanna International Group, LLP Pyxis Oncology, Inc. Call Options Transaction History

Susquehanna International Group, LLP

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$2.83 - $3.94 $3,962 - $5,516	1,400 Added 6.25%	23,800 $87,000
Q2 2024 Aug 15, 2024	SELL	$3.06 - $5.58 $38,250 - $69,750	-12,500 Reduced 35.82%	22,400 $74,000
Q1 2024 May 07, 2024	BUY	$2.03 - $6.59 $49,531 - $160,796	24,400 Added 232.38%	34,900 $148,000
Q4 2023 Feb 14, 2024	SELL	$1.4 - $2.09 $18,340 - $27,378	-13,100 Reduced 55.51%	10,500 $18,000
Q3 2023 Nov 14, 2023	SELL	$1.6 - $2.78 $6,080 - $10,564	-3,800 Reduced 13.87%	23,600 $46,000
Q2 2023 Aug 11, 2023	BUY	$2.46 - $4.07 $67,404 - $111,518	27,400 New	27,400 $70,000

101

28.2M

539K

54.1K

Ticker PYXS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,096,400
Market Cap $59.3M
Description
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.